Beyond Basic Beta Channel Weight Loss Drugs Could Prove Potent for PPH By Tom LydonSeptember 11, 2023
Beyond Basic Beta Channel Growth, Innovation Could Fuel Pharma ETF Rebound By Tom LydonDecember 21, 2022
Beyond Basic Beta Channel PPH Is Home to Some of the Top Healthcare Stocks By Tom LydonOctober 18, 2022
Beyond Basic Beta Channel Pharma Stocks, ETFs Can Deal With Drug Pricing Legislation By Tom LydonJuly 27, 2022
Beyond Basic Beta Channel Pharmaceuticals Stocks, ETFs Could Have Power Beyond 2022 By Tom LydonFebruary 4, 2022
Beyond Basic Beta Channel Pharma Could Be Place to Be for Healthcare Winners, Value By Tom LydonJanuary 7, 2022
Beyond Basic Beta Channel Write a Prescription for Pharma Dividends With PPH By Tom LydonDecember 9, 2021
Beyond Basic Beta Channel Omicron Variant Could Be Potent for Pharma Stocks, ETFs By Tom LydonDecember 2, 2021
Beyond Basic Beta Channel PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth By Tom LydonNovember 9, 2021
Beyond Basic Beta Channel Alzheimer’s Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight By Tom LydonAugust 5, 2021
Beyond Basic Beta Channel Artificial Intelligence Set to Transform the Pharmaceutical Industry By Ben HernandezJune 1, 2021
Beyond Basic Beta Channel Pharma Goes Beyond the Vaccine. ‘PPH’ on the Verge of More Advances By Ben HernandezMarch 4, 2021
Nasdaq Investment Intelligence Channel Beyond the Vaccine: The Long Runway for Health and Pharmaceutical ETFs By Tom LydonNovember 25, 2020
